Ullmann Wealth Partners Group LLC Lowers Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Ullmann Wealth Partners Group LLC cut its position in HCA Healthcare, Inc. (NYSE:HCA) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,802 shares of the company’s stock after selling 42 shares during the period. Ullmann Wealth Partners Group LLC’s holdings in HCA Healthcare were worth $2,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. bought a new position in shares of HCA Healthcare during the second quarter worth $33,000. Legacy Investment Solutions LLC purchased a new position in shares of HCA Healthcare during the third quarter valued at about $39,000. Canoe Financial LP bought a new position in HCA Healthcare during the third quarter valued at approximately $41,000. Capital Performance Advisors LLP bought a new stake in HCA Healthcare in the third quarter worth $41,000. Finally, Northwest Investment Counselors LLC purchased a new stake in HCA Healthcare during the 3rd quarter valued at $44,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now directly owns 52,702 shares in the company, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. The trade was a 29.76 % decrease in their position. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.

HCA Healthcare Stock Performance

Shares of HCA stock opened at $309.26 on Friday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The company has a market cap of $78.34 billion, a PE ratio of 13.89, a PEG ratio of 1.03 and a beta of 1.64. HCA Healthcare, Inc. has a 12-month low of $276.50 and a 12-month high of $417.14. The business’s fifty day simple moving average is $318.49 and its 200-day simple moving average is $353.11.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 27th. Stockholders of record on Friday, December 13th were paid a dividend of $0.66 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.85%. HCA Healthcare’s payout ratio is 11.85%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. restated a “neutral” rating and issued a $380.00 target price on shares of HCA Healthcare in a report on Tuesday, December 17th. TD Cowen reduced their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a report on Monday, October 28th. Morgan Stanley cut their price objective on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Barclays cut their price target on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Finally, Truist Financial reduced their target price on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, HCA Healthcare has a consensus rating of “Moderate Buy” and an average target price of $385.27.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.